Targeting the Tumor Vasculature for Prostate Cancer Immunotherapy
Abstract
The efficacy and safety for prostate cancer immunotherapy of several Icon delivery systems were tested in immunocompetent mice carrying the mouse prostatic tumor, and in SCID mice carrying a human prostatic tumor, as follows. (i) Alginate and thermosensitive gels containing Icon-producer CHO or BHK cells were injected subcutaneously or intratumorally. The procedures showed efficacy but the cells escaped from the gel to form nodules. (ii) 293 cells containing infected with an adenoviral vector encoding the Icon were injected subcutaneously or intratumorally. The procedures were efficacious and safe and will be studied further as promising delivery systems. (iii) Icon-producer mouse NIH-3T3 cells were inserted into a chamber and implanted inside a skinfold flap in the mouse. The cells secreted the Icon for about 7 weeks and inhibited tumor growth. This procedure could be continued for longer periods by periodic implantation of chambers with fresh cells. (iv) Intravenous injections of purified Icon protein, or intratumoral injections of an adenoviral vector encoding the Icon, into SCID mice carrying human prostate tumors resulted in long-term regression of the tumors without toxicity. We conclude that the delivery procedures for the Icon described in parts ii, iii and iv showed significant efficacy and safety in mouse models and should be developed for possible clinical use.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2004
- Accession Number
- ADA424646
Entities
People
- Alan Garen
Organizations
- Yale University